The presentation and medical course of PCOS in adolescents across the United States

美国青少年多囊卵巢综合症的表现和医学过程

基本信息

  • 批准号:
    10667067
  • 负责人:
  • 金额:
    $ 38.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-05 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

1 Polycystic ovary syndrome (PCOS), one of the most common endocrinopathies in women, presents with 2 anovulation and hyperandrogenism in adolescence. In addition to reproductive abnormalities, PCOS is 3 frequently associated with obesity and metabolic complications including diabetes, non-alcoholic fatty liver 4 disease, obstructive sleep apnea, hypertension and hyperlipidemia. Additionally, women with PCOS are more 5 likely to suffer from mental health disorders and significant dermatologic manifestations. PCOS is a chronic 6 heterogeneous familial disorder and thus symptoms, signs and co-morbidities at time of diagnosis vary. Despite 7 the high prevalence and gravity of comorbidities associated with PCOS, widely effective therapeutic options are 8 lacking. Recommended therapies for PCOS treatment in women not seeking pregnancy include estrogen 9 containing contraceptives (EC), lifestyle modification, and metformin. Recently there has been a call for more 10 individualized and personalized therapeutic approaches, however there is little biologic basis to recommend one 11 therapy over another. Further, despite the availability of these treatment options for over 40 years, research on 12 their efficacy in youth with PCOS is limited to small studies. Additionally, due to puberty specific hormone 13 changes, adolescents have lower insulin sensitivity than adults. Indeed, a number of studies have established 14 that youth with diabetes or obesity respond less to metformin than adults. Thus, data from medication trials in 15 adult women cannot be applied in youth with PCOS. 16 No mechanism is currently available in the United States to query the early natural history and response to 17 existing medications in a diverse population of youth with PCOS. Using 18 institutions, e found that reproductive abnormalities are more severe in girls without obesity, and metabolic 19 co-morbidities are more common in girls with obesity. Additionally, we and others have found that PCOS 20 presentation, especially as relates to comorbidities, may reflect underling racial and ethnic differences. The 21 overall goal of the project is to describe the presenting reproductive and metabolic phenotypes, natural history, 22 and response to therapy in a large sample of geographically, ethnically and racially diverse youth with PCOS. We 23 hypothesize that presentations of PCOS in adolescence will vary by family history, obesity, and race and ethnicity 24 status, and that unique factors at diagnosis can be used to identify those that respond to EC, metformin or 25 lifestyle therapies. SA1) Describe the presentation and co-morbidities at the time of diagnosis of PCOS in youth 26 in the United States SA2) Determine the response to common medications (lifestyle, EC, metformin). This 27 cohort represents a very diverse population of youth with PCOS, and the database is the first of its kind for youth 28 with PCOS. This work will establish how early phenotypes can inform more individualized approaches toward 29 initial therapy. These efforts are a critical first step towards developing data-informed personalized treatment 30 plans to improve the long-term health of girls with PCOS. pooled retrospective data from 6 w
1多囊卵巢综合征(PCOS)是女性最常见的内分泌疾病之一, 2青春期无排卵与高雄激素血症。除了生殖异常,PCOS是 3.常伴有肥胖和代谢并发症,包括糖尿病、非酒精性脂肪肝 4疾病,阻塞性睡眠呼吸暂停,高血压和高脂血症。此外,患有PCOS的女性 5可能患有精神健康疾病和显著的皮肤病表现。PCOS是一种慢性 6异质性家族性疾病,因此诊断时的症状、体征和共病各不相同。尽管 PCOS合并症的高患病率和严重性,广泛有效的治疗选择是 8缺少推荐的治疗PCOS的妇女不寻求怀孕包括雌激素 9含有避孕药(EC),生活方式改变和二甲双胍。最近有一个呼吁, 10种个性化和个性化的治疗方法,但几乎没有生物学基础推荐一种 11治疗另一个。此外,尽管这些治疗方案的可用性超过40年, 12他们对PCOS青年的疗效仅限于小型研究。此外,由于青春期特有的激素 13变化,青少年胰岛素敏感性低于成人。事实上,许多研究已经证实, 糖尿病或肥胖青年对二甲双胍的反应低于成年人。因此,来自药物试验的数据 15成年女性不能应用于患有PCOS的青年。 16.美国目前没有任何机制可以查询早期自然历史和对 17种现有药物在不同的PCOS青年人群中使用 18个机构,e发现生殖异常在没有肥胖的女孩中更严重, 19合并症在肥胖女孩中更常见。此外,我们和其他人发现PCOS 20表现,特别是与合并症有关的表现,可能反映了潜在的种族和民族差异。的 该项目的总体目标是描述目前的生殖和代谢表型,自然史, 22和对治疗的反应在地理上,种族和种族多样化的PCOS青年的大样本。我们 23假设青春期多囊卵巢综合征的表现因家族史、肥胖、种族和民族而异 24状态,并且诊断时的独特因素可用于识别对EC,二甲双胍或 25种生活方式疗法SA1)描述年轻人诊断PCOS时的表现和合并症 美国26例SA2)确定对常见药物(生活方式、EC、二甲双胍)的反应。这 27队列代表了非常多样化的PCOS青年人群,该数据库是第一个针对青年的数据库。 28、PCOS这项工作将确定早期表型如何为更个性化的方法提供信息, 29第一次治疗这些努力是朝着开发基于数据的个性化治疗迈出的关键的第一步 30项计划旨在改善PCOS女孩的长期健康。 6例患者的汇总回顾性数据 W

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Melanie G Cree其他文献

Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood
从青春期到成年期多囊卵巢综合征综合护理的转变
  • DOI:
    10.1016/s2352-4642(24)00019-1
  • 发表时间:
    2024-06-01
  • 期刊:
  • 影响因子:
    15.500
  • 作者:
    Stacey L Simon;Phoutdavone Phimphasone-Brady;Kathryn M McKenney;Lauren D Gulley;Andrea E Bonny;Jaime M Moore;Carla Torres-Zegarra;Melanie G Cree
  • 通讯作者:
    Melanie G Cree
PPAR-α agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial
  • DOI:
    10.1186/1743-7075-4-9
  • 发表时间:
    2007-01-01
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    Melanie G Cree;Bradley R Newcomer;David N Herndon;Ting Qian;Dayoung Sun;Beatrice Morio;Jennifer J Zwetsloot;G Lynis Dohm;Ricki Y Fram;Ronald P Mlcak;Asle Aarsland;Robert R Wolfe
  • 通讯作者:
    Robert R Wolfe

Melanie G Cree的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Melanie G Cree', 18)}}的其他基金

Role of semaglutide in restoring ovulation in youth and adults with polycystic ovary syndrome
索马鲁肽在青少年和成人多囊卵巢综合征恢复排卵中的作用
  • 批准号:
    10587181
  • 财政年份:
    2023
  • 资助金额:
    $ 38.17万
  • 项目类别:
Impact of GLP-1 on Hepatic Fat and Energy Utilization in Obese Girls with Polycystic Ovarian Syndrome
GLP-1 对患有多囊卵巢综合症的肥胖女孩肝脏脂肪和能量利用的影响
  • 批准号:
    10212375
  • 财政年份:
    2019
  • 资助金额:
    $ 38.17万
  • 项目类别:
Impact of GLP-1 on Hepatic Fat and Energy Utilization in Obese Girls with Polycystic Ovarian Syndrome
GLP-1 对患有多囊卵巢综合症的肥胖女孩肝脏脂肪和能量利用的影响
  • 批准号:
    10459276
  • 财政年份:
    2019
  • 资助金额:
    $ 38.17万
  • 项目类别:
Impact of GLP-1 on Hepatic Fat and Energy Utilization in Obese Girls with Polycystic Ovarian Syndrome
GLP-1 对患有多囊卵巢综合症的肥胖女孩肝脏脂肪和能量利用的影响
  • 批准号:
    9981737
  • 财政年份:
    2019
  • 资助金额:
    $ 38.17万
  • 项目类别:

相似海外基金

Metagenomic discovery and optimization of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris
针对痤疮皮肤杆菌治疗寻常痤疮的新型内溶素的宏基因组发现和优化
  • 批准号:
    10821291
  • 财政年份:
    2023
  • 资助金额:
    $ 38.17万
  • 项目类别:
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
用于口服治疗顽固性结节性痤疮的选择性 CYP26 抑制剂。
  • 批准号:
    10822482
  • 财政年份:
    2023
  • 资助金额:
    $ 38.17万
  • 项目类别:
ENLIGHT : Light-sensitive Engineered Living Material for acne therapy
ENLIGHT:用于痤疮治疗的光敏工程活性材料
  • 批准号:
    EP/Y03029X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38.17万
  • 项目类别:
    Fellowship
Developing a novel medical-grade microneedle patch to treat acne vulgaris
开发一种新型医用级微针贴片来治疗寻常痤疮
  • 批准号:
    10053162
  • 财政年份:
    2023
  • 资助金额:
    $ 38.17万
  • 项目类别:
    Collaborative R&D
Smart Photodynamic Therapy for Acne by Reversibly Switchable Intersystem Crossing in Pure Organic Materials
通过纯有机材料中的可逆可切换系间交叉来治疗痤疮的智能光动力疗法
  • 批准号:
    10483461
  • 财政年份:
    2022
  • 资助金额:
    $ 38.17万
  • 项目类别:
Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris
寻常痤疮中 Th17 细胞外陷阱介导的抗菌宿主防御
  • 批准号:
    10502200
  • 财政年份:
    2022
  • 资助金额:
    $ 38.17万
  • 项目类别:
Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris
寻常痤疮中 Th17 细胞外陷阱介导的抗菌宿主防御
  • 批准号:
    10698121
  • 财政年份:
    2022
  • 资助金额:
    $ 38.17万
  • 项目类别:
Acne: a disease of lipid metabolism, microbiome and the immune response
痤疮:一种脂质代谢、微生物组和免疫反应疾病
  • 批准号:
    10404440
  • 财政年份:
    2022
  • 资助金额:
    $ 38.17万
  • 项目类别:
Acne: a disease of lipid metabolism, microbiome and the immune response
痤疮:一种脂质代谢、微生物组和免疫反应疾病
  • 批准号:
    10404436
  • 财政年份:
    2022
  • 资助金额:
    $ 38.17万
  • 项目类别:
Study of colonization mechanism of high pathogenic Cutibacterium acnes in patients with acne and healthy individuals
高致病性痤疮皮肤杆菌在痤疮患者和健康个体中的定植机制研究
  • 批准号:
    21K15303
  • 财政年份:
    2021
  • 资助金额:
    $ 38.17万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了